Regulation of intracellular glucocorticoid concentrations
US6368816B2 · kind B2 · utility
48Cited by
0References
1Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 27, 1998 |
| Grant date | Apr 9, 2002 |
| Priority date | — |
| Expiry date | Feb 27, 2018 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P25/24
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The interconversion of inactive 11-keto steroids with their active 11&bgr;-hydroxy equivalents can be controlled by the use of inhibitors of the 11&bgr;-reductase enzyme, such as carbenoxolone (3&bgr;-(3-carboxypropionyloxy)-11-oxo-olean-2-en30-oic acid). Such inhibitors may be put to a number of therapeutic uses in humans and animals, for instance to inhibit hepatic gluconeogenesis, to lower intracellular cortisol concentration, to increase insulin sensitivity in adipose tissue and muscle, and to prevent or reduce neuronal loss/cognitive impaiment due to glucocorticoid potentiated neurotoxicity or neural dysfunction or damage.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.